QT Imaging Records New Milestone Success With Blinded Medical

San Francisco, California, U.S., August 04, 2022 (GLOBE NEWSWIRE) — Last year US Capital Global Securities LLC launched a convertible bond offering of up to $30 million for QT Imaging, Inc. (“QT Imaging”), an innovative MedTech company that continually achieves new milestones in product development, testing and release. In QT Imaging’s latest milestone, a prostate cancer screening study conducted by the National Cancer Institute has shown that its proprietary product, the QTscan®, has sensitivity equal to or better than MRI.

The QTscan is FDA cleared for whole breast imaging and can be used for medical screening and diagnosis. With proven superior sensitivity and specificity for X-ray mammography, the QTscan can confidently tell the difference between benign and problematic tissue without the need for compression, injections and potentially harmful radiation.

Recently, the QTscan was also subjected to a second (BR15) blinded multi-reader multi-case study conducted by Dr. Yulei Jiang, PhD, from the University of Chicago Department of Radiology. The results show that the QTscan meets the non-inferiority endpoint for breast cancer detection compared to conventional full-field digital mammography.

“We are very pleased, although not at all surprised, with these positive results, which demonstrate the long-term and sustained high performance of our QTscan,” said John C. Klock, MD, CEO and Chief Medical Officer at QT Imaging. “The results are particularly exciting for young women who are at high risk of developing breast cancer due to genetic risk factors but do not currently qualify for mammography. QT Imaging’s technology finally gives them a safe and effective way to assess breast screening.”

“We are extremely proud to support QT Imaging in the development of this innovative, groundbreaking, non-invasive body scanning technology,” he said Karl Towle, CEO of US Capital Global Securities. “The QT scan is…